OnKure Therapeutics’ (OKUR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR) in a research note issued to investors on Thursday, MarketBeat.com reports. They currently have a $40.00 price target on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q1 2025 earnings at ($1.12) EPS, Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.21) EPS.

A number of other research firms also recently weighed in on OKUR. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Oppenheimer started coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They set an “outperform” rating and a $35.00 price objective on the stock.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR opened at $17.95 on Thursday. The stock has a market cap of $59.95 million, a P/E ratio of -1.07 and a beta of 0.21. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $86.70.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.